Rivastigmine Reduces “Likely to Use Methamphetamine” in Methamphetamine-Dependent Volunteers

We previously reported that treatment with the cholinesterase inhibitor rivastigmine (3 mg, PO for 5 days) significantly attenuated “Desire for METH”. Given that higher dosages of rivastigmine produce greater increases in synaptic ACh, we predicted that 6 mg should have more pronounced effects on cr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: De La Garza, R., Newton, T.F., Haile, C.N., Yoon, J.H., Nerumalla, C.S., Mahoney, J.J., Aziziyeh, A.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877939/
https://ncbi.nlm.nih.gov/pubmed/22230648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pnpbp.2011.12.014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires